AU2016329005A1 - Treatment of neurodegenerative diseases - Google Patents

Treatment of neurodegenerative diseases Download PDF

Info

Publication number
AU2016329005A1
AU2016329005A1 AU2016329005A AU2016329005A AU2016329005A1 AU 2016329005 A1 AU2016329005 A1 AU 2016329005A1 AU 2016329005 A AU2016329005 A AU 2016329005A AU 2016329005 A AU2016329005 A AU 2016329005A AU 2016329005 A1 AU2016329005 A1 AU 2016329005A1
Authority
AU
Australia
Prior art keywords
inhibitor
signalling
egfr
myd88
gefitinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016329005A
Other languages
English (en)
Inventor
Laura FERRAIUOLO
Richard Mead
Kenneth Patrick Mulvany
Peter Richardson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BenevolentAI Bio Ltd
Original Assignee
BenevolentAI Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BenevolentAI Bio Ltd filed Critical BenevolentAI Bio Ltd
Publication of AU2016329005A1 publication Critical patent/AU2016329005A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2016329005A 2015-09-24 2016-09-23 Treatment of neurodegenerative diseases Abandoned AU2016329005A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1516905.5 2015-09-24
GBGB1516905.5A GB201516905D0 (en) 2015-09-24 2015-09-24 Treatment of Neurodegenerative diseases
PCT/GB2016/052970 WO2017051188A1 (en) 2015-09-24 2016-09-23 Treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
AU2016329005A1 true AU2016329005A1 (en) 2018-04-19

Family

ID=54544061

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016329005A Abandoned AU2016329005A1 (en) 2015-09-24 2016-09-23 Treatment of neurodegenerative diseases

Country Status (13)

Country Link
US (1) US20180263992A1 (cg-RX-API-DMAC10.html)
EP (1) EP3352759A1 (cg-RX-API-DMAC10.html)
JP (1) JP6893917B2 (cg-RX-API-DMAC10.html)
KR (1) KR20180056695A (cg-RX-API-DMAC10.html)
CN (1) CN108025005A (cg-RX-API-DMAC10.html)
AU (1) AU2016329005A1 (cg-RX-API-DMAC10.html)
BR (1) BR112018005855A2 (cg-RX-API-DMAC10.html)
CA (1) CA2999390A1 (cg-RX-API-DMAC10.html)
EA (1) EA201890647A1 (cg-RX-API-DMAC10.html)
GB (1) GB201516905D0 (cg-RX-API-DMAC10.html)
MA (1) MA42930A (cg-RX-API-DMAC10.html)
MX (1) MX2018003619A (cg-RX-API-DMAC10.html)
WO (1) WO2017051188A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117338784A (zh) * 2020-08-26 2024-01-05 长庚大学 一种酪氨酸激酶抑制剂在制造用以治疗因炎性体激活所致相关疾病的药物中的用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170335324A1 (en) 2014-11-12 2017-11-23 The General Hospital Corporation Methods for treating neurodegenerative diseases
GB201714303D0 (en) * 2017-09-06 2017-10-18 Benevolentai Ltd Treatment of neurodegenerative diseases
GB201714311D0 (en) * 2017-09-06 2017-10-18 Benevolentai Ltd Treatment of neurodegenerative diseases
GB201714316D0 (en) * 2017-09-06 2017-10-18 Benevolentai Ltd Treatement of neurodegenerative diseases
GB201714307D0 (en) * 2017-09-06 2017-10-18 Benevolentai Ltd Treatment of neurodegenerative diseases
CN108853111B (zh) * 2018-08-07 2020-06-05 浙江大学 一种组合物在制备治疗吉非替尼肝脏毒性药物中的应用
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
CN113694047A (zh) * 2021-08-31 2021-11-26 杭州师范大学 β-石竹烯在制备抗肿瘤药物中的应用
WO2025152803A1 (zh) * 2024-01-17 2025-07-24 四川大学 一种靶向traf6的多肽及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US257403A (en) * 1882-05-02 Electric lighting apparatus
US62342A (en) * 1867-02-26 Improved tool for the manufacture of paper bags
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
AU2003241398A1 (en) * 2002-05-06 2003-11-17 Washington University Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
JP4328500B2 (ja) * 2002-07-25 2009-09-09 独立行政法人農業・食品産業技術総合研究機構 中枢神経細胞突起再生剤及びその薬理作用を有する高機能性製品
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
US7547794B2 (en) * 2003-04-03 2009-06-16 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
EP1714960B1 (en) * 2004-02-09 2018-03-28 Mitsubishi Tanabe Pharma Corporation Novel therapeutic agent for amyotrophic lateral sclerosis (als) or disease attributable to als
NZ556673A (en) * 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
US7449442B2 (en) * 2005-07-12 2008-11-11 Children's Medical Center Corporation EGFR inhibitors promote axon regeneration
JP2008061505A (ja) * 2006-09-04 2008-03-21 Hisamitsu Pharmaceut Co Inc 筋萎縮性側索硬化症の治療剤のスクリーニング方法
WO2010017541A2 (en) * 2008-08-08 2010-02-11 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
EA201290041A1 (ru) * 2009-08-06 2012-07-30 Ньюралтус Фармасьютикалс, Инк. Лечение расстройств, связанных с макрофагами
SG10201406763WA (en) * 2009-10-22 2014-11-27 Genentech Inc Modulation of axon degeneration
IN2015MN00408A (cg-RX-API-DMAC10.html) * 2012-07-27 2015-09-04 Antonius Martinus Gustave Bunt

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117338784A (zh) * 2020-08-26 2024-01-05 长庚大学 一种酪氨酸激酶抑制剂在制造用以治疗因炎性体激活所致相关疾病的药物中的用途

Also Published As

Publication number Publication date
JP6893917B2 (ja) 2021-06-23
CA2999390A1 (en) 2017-03-30
US20180263992A1 (en) 2018-09-20
MA42930A (fr) 2018-08-01
JP2018534259A (ja) 2018-11-22
MX2018003619A (es) 2018-08-01
CN108025005A (zh) 2018-05-11
EP3352759A1 (en) 2018-08-01
KR20180056695A (ko) 2018-05-29
EA201890647A1 (ru) 2018-09-28
WO2017051188A1 (en) 2017-03-30
BR112018005855A2 (pt) 2018-10-16
GB201516905D0 (en) 2015-11-11

Similar Documents

Publication Publication Date Title
US20180263992A1 (en) Treatment of neurodegenerative diseases
Vigneswara et al. Pigment epithelium-derived factor is retinal ganglion cell neuroprotective and axogenic after optic nerve crush injury
Dabouz et al. An allosteric interleukin-1 receptor modulator mitigates inflammation and photoreceptor toxicity in a model of retinal degeneration
JP2020518642A (ja) 難聴の予防および治療のための組成物および方法
WO2016135046A1 (en) Inhibitors of raf1, mst1, and pkl1 for use in the treatment of a retrovirus
ES2962526T3 (es) Secretagogos PAR-4 para el tratamiento del cáncer
Tang et al. Neuroprotective role of an N-acetyl serotonin derivative via activation of tropomyosin-related kinase receptor B after subarachnoid hemorrhage in a rat model
US20230026808A1 (en) Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury
US20140302009A1 (en) Medicinal Agent for Prevention or Treatment of Diseases Associated with Intraocular Neovascularization and/or Intraocular Vascular Hyperpermeability
WO2019048852A1 (en) TREATMENT OF NEURODEGENERATIVE DISEASES
AU2020279003B2 (en) Oxathiazin compounds for inhibiting GAPDH
US20210069189A1 (en) Treatment of neurodegenerative diseases
AU2013223965C1 (en) Compositions and methods for the treatment of retinal degeneration
KR20220014818A (ko) 스트렙토니그린 및 면역관문 억제제를 유효성분으로 포함하는 대장암 예방 및 치료용 조성물
WO2019048851A1 (en) TREATMENT OF NEURODEGENERATIVE DISEASES
US9669068B2 (en) Methods for the treatment of cancer using gliadin peptides
WO2019048853A1 (en) TREATMENT OF NEURODEGENERATIVE DISEASES
US20220323452A1 (en) Methods and compositions for inhibiting gapdh
US20240165113A1 (en) Methods of treatment for leukemia
HK40079687A (en) Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury
Battaglia et al. Activation of mGlu3 Receptors Stimulates the Production of GDNF in Striatal
II et al. Neuroprotection in Glaucoma

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application